Navigation Links
Nile Therapeutics to Present at BIO Investor Forum
Date:9/30/2010

SAN MATEO, Calif., Sept. 30 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that Daron Evans, Chief Financial Officer, will present at the 9th Annual BIO Investor Forum Wednesday, October 6, 2010 at 8:30 a.m. (Pacific Time) at the Palace Hotel in San Francisco, California.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally-designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events c
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... FREMONT, Calif. , May 5, 2015 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and ... 2a clinical trial evaluating tenapanor in Stage 3 ... mellitus and albuminuria did not meet the primary ... tenapanor-treated patients compared to patients receiving placebo. ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - ... Laval and known under the « ... the closing of the transaction previously announced on April ... issued and outstanding  shares of Orthoconcept (2008) inc.   ... 500 000 common shares (TSXV: ERG) to the vending ...
(Date:5/5/2015)... -- The preclinical contract research organization Absorption Systems , ... safety testing of medical devices, announces that Dr. ... at this week,s annual meeting of The Association for ... Denver, CO. The title of Dr. Gum,s ... Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) Polymer in a Rabbit ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3
... aureus and, Methicillin-Resistant Staphylococcus aureus from Positive ... BD Diagnostics, a segment,of BD (Becton, Dickinson and ... it,received clearance from the U.S. Food and Drug ... new assay is the first test available to,rapidly ...
... Dec. 27 Allos,Therapeutics, Inc. (Nasdaq: ALTH ... (DMC) has completed the pre-specified 65-patient,safety review of ... trial of,PDX (pralatrexate) in patients with relapsed or ... the trial continue per the,protocol. This interim assessment ...
Cached Medicine Technology:BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 2BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
(Date:5/5/2015)... Nutritional science and medical research has enabled ... health conditions and illnesses linked to carrying excess weight. ... eating methods to rid the body of dangerous toxins, ... fast and processed foods. Patients find the company’s ... report feeling better and losing excess fat within days. ...
(Date:5/5/2015)... In a April 25, 2015, report published ... the Missouri State Highway Patrol (MSHP) announced that Indiana led ... for the second year in a row. , The ... 1,469 incidents in 2014 alone, around 15% of the national ... the US Population calls Indiana home, according to the report. ...
(Date:5/5/2015)... Information Innovators Inc. (“Triple-i”), ... government, today announced its acquisition of Creative ... exclusively to federal government customers through its highly ... health services, and program management support. The company ... a Third Party Assessment Organization (3PAO) for cloud ...
(Date:5/5/2015)... Freeport, Grand Bahama (PRWEB) May 05, 2015 ... published its Orthopedic Lifestyle Report today. The study was ... orthopedic conditions such as osteoarthritis and sports-related ... chronic pain and stiffness was the most prevalent symptom ... reduced functionality such as walking, standing and bending over. ...
(Date:5/5/2015)... 2015 Barnabas Health, the state’s largest ... a new healthy cooking video series starring celebrity chef ... Bravo’s Top Chef, teamed up with Barnabas Health to ... living. In support of the series, Barnabas Health ... videos will be showcased on social media. ...
Breaking Medicine News(10 mins):Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:Barnabas Health Teams Up With Celebrity Chef Sam Talbot To Launch "Life Is Better Healthy" Cooking Video Series 2Health News:Barnabas Health Teams Up With Celebrity Chef Sam Talbot To Launch "Life Is Better Healthy" Cooking Video Series 3
... the most dependent on,others and the ones the least ... expert. "Why do children exhibit psychological trauma? There ... of their parents and the predictability,of their physical environment. ... psychologist Robert R. Butterworth, Ph.D. Dr. Butterworth added, ...
... Komen Detroit Race for the Cure Joins Nationwide Campaign ... Deadlier for Low-Income Women and Women of Color, ... Cure,physicians and executives from five of metro Detroit,s top ... cancer survivors,and advocates this evening at a "Close the ...
... children with attention deficit hyperactivity disorder (ADHD) at the ... missing: the fathers., Fabiano, an assistant professor in the Graduate ... graduate assistant at the UB Center for Children and ... helped more than 2,500 children with behavioral, emotional and ...
... Conference Call to be held on November 13, 2007 ... / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong), ... Inc. (NYSE: WX ) ("WuXi PharmaTech" or "the ... company, today announced that it will release unaudited,financial results ...
... Science,Corporation (Nasdaq: CSCX ), a global leader ... that it will release its third,quarter 2007 financial ... close. The Company has scheduled a conference call ... to discuss the financial results for,the third quarter ...
... discovery of suitable molecular targets cellular molecules along ... comes the perplexing dilemma of where to find ... those targets. While the possibilities for drug designs are ... are often problematic or ill-suited for the particular needs ...
Cached Medicine News:Health News:California Wildfires - Psychological Effects; Children ... Psychologist Is Available to Discuss Trauma 2Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 2Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 3Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 4Health News:Getting fathers involved in children's ADHD treatment programs 2Health News:Getting fathers involved in children's ADHD treatment programs 3Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 2Health News:WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007 3Health News:Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 2Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 2Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 3Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 4Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 5Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 6Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 7Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 8
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
The ToxCup Drug Screen Cup is a one-step test for the rapid detection of up to five drugs of abuse and four adulteration tests. It's design integrates sample collection, drug/adulteration testing and...
Lasts up to 3 months , Absorbable copolymer of glycolic acid and trimethylene carbonate , Designed to provide relief from short term dry eye conditions. , Appropriate for surgery-related d...
... transconjunctival self-retaining infusion cannulas for use in ... some benefit to patients that present with ... lessening the occurrence of suture induced astigmatism. ... and does not require a blade for ...
Medicine Products: